INT9842

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1992
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 36
Total Number 37
Disease Relevance 22.79
Pain Relevance 4.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (F2) extracellular space (F2) extracellular region (F2)
plasma membrane (F2)
Anatomy Link Frequency
platelet 4
plasma 2
Portal vein 1
heart 1
F2 (Homo sapiens)
F2 - G20210A (4)
Pain Link Frequency Relevance Heat
Analgesic 1 99.56 Very High Very High Very High
cytokine 224 99.32 Very High Very High Very High
Inflammation 326 99.12 Very High Very High Very High
Restless leg syndrome 60 99.08 Very High Very High Very High
Desipramine 1 98.84 Very High Very High Very High
cva 312 98.44 Very High Very High Very High
tricyclic antidepressant 3 98.04 Very High Very High Very High
chemokine 8 92.88 High High
Inflammatory marker 7 92.40 High High
Migraine 1 91.20 High High
Disease Link Frequency Relevance Heat
Myelodysplastic Syndromes 2 100.00 Very High Very High Very High
Thrombosis Related Under Development 233 99.98 Very High Very High Very High
Cv Unclassified Under Development 19 99.98 Very High Very High Very High
Pre-eclampsia 344 99.92 Very High Very High Very High
Habitual Abortion 90 99.80 Very High Very High Very High
Hyperhomocysteinemia 49 99.76 Very High Very High Very High
Anti-phospholipid Antibody Syndrome 158 99.56 Very High Very High Very High
Coagulation Disorder 41 99.50 Very High Very High Very High
Stroke 66 99.28 Very High Very High Very High
Thrombosis 400 99.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Moreover, the venom of the Naja n. nigricollis consists of phospholipase A2 (an anticoagulant enzyme which inhibits the prothrombinase complex by its binding to coagulation factor Xa) [9, 10] and cardiotoxin [11].
prothrombin Binding (binding) of
1) Confidence 0.47 Published 2010 Journal Journal of Toxicology Section Body Doc Link PMC2902021 Disease Relevance 1.17 Pain Relevance 0.24
To investigate a possible association between the human prothrombin gene G20210A polymorphism and coronary artery thrombosis, we screened 172 consecutive patients with ischaemic heart disease admitted for coronary arteriography.
prothrombin gene (G20210A) Binding (association) of in heart associated with coronary artery disease and thrombosis
2) Confidence 0.37 Published 2002 Journal Blood Coagul. Fibrinolysis Section Abstract Doc Link 12439145 Disease Relevance 0.61 Pain Relevance 0.14
[Cerebral and systemic venous thrombosis associated to prothrombin G20210 mutation: case report].
prothrombin G20210 mutation Binding (associated) of associated with thrombosis related under development
3) Confidence 0.37 Published 2003 Journal Arq Neuropsiquiatr Section Title Doc Link 14762616 Disease Relevance 0.84 Pain Relevance 0.17
Heterozygous prothrombin 20210G/A mutation, associated with hyperhomocysteinemia, and homozygous methylenetetrahydrofolate reductase 677C/T mutation, in a patient with portal and mesenteric venous thrombosis.
prothrombin Binding (associated) of associated with thrombosis related under development and hyperhomocysteinemia
4) Confidence 0.36 Published 2004 Journal Hematol. J. Section Title Doc Link 15570301 Disease Relevance 0.63 Pain Relevance 0.09
Platelet activation markers for ex vivo analysis may include a) activation-dependent epitopes of the membrane glycoprotein (GP) IIb/IIIa (CD41a) receptor, as demonstrated by the binding of activation-specific monoclonal antibodies (MoAbs) PAC1, anti-LIBS1 and anti-RIBS); b) the expression of P-selectin (CD62p), the alpha-granule GP translocated to the platelet surface following release reaction; and c) platelet procoagulant activity, as demonstrated by the binding of i) annexin V protein to the prothrombinase-complex (prothrombin, activated factor X (Xa) and V (Va)) binding sites on the surface of activated platelets, and of ii) MoAbs against activated coagulation factors V and X bound to the surface of activated platelets.
prothrombin Binding (binding) of in Platelet
5) Confidence 0.36 Published 2004 Journal J. Biol. Regul. Homeost. Agents Section Abstract Doc Link 15471223 Disease Relevance 0.33 Pain Relevance 0.10
These drugs differ with respect to thrombin binding sites, reversibility, pharmacology, and specific indications.35
thrombin Binding (binding) of
6) Confidence 0.36 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 0.61 Pain Relevance 0.12
In present medical practice the natural thrombin inhibitor – heparin and its low-molecular fragments are widely used, which act by formation of the triple complex with thrombin and antithrombin III– as anticoagulants of direct action (Mousa SA.
thrombin Binding (formation) of
7) Confidence 0.35 Published 2008 Journal The Open Biochemistry Journal Section Body Doc Link PMC2627521 Disease Relevance 0.24 Pain Relevance 0.14
Importantly, a similar increase in sCD40L release correlated with thrombin formation has been reported in patients with the metabolic syndrome (24).
thrombin Binding (formation) of associated with metabolic syndrome
8) Confidence 0.30 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494657 Disease Relevance 0.79 Pain Relevance 0
Thrombin formation
Thrombin Binding (formation) of
9) Confidence 0.30 Published 2008 Journal Diabetes Care Section Body Doc Link PMC2494657 Disease Relevance 0.77 Pain Relevance 0.06
Prothrombin complex concentrates contain the vitamin K-dependent coagulation factors.
Prothrombin Binding (complex) of
10) Confidence 0.28 Published 2006 Journal Crit Care Section Body Doc Link PMC1750988 Disease Relevance 0.87 Pain Relevance 0.08
[Portal vein thrombosis associated with a myeloproliferative disorder, prothrombin G20210A mutation, antiphospholipid syndrome, with repermeation during anticoagulant therapy].
prothrombin G20210A (G20210A) Binding (associated) of in Portal vein associated with anti-phospholipid antibody syndrome, cv unclassified under development and myelodysplastic syndromes
11) Confidence 0.28 Published 2001 Journal Gastroenterol. Clin. Biol. Section Title Doc Link 11521110 Disease Relevance 1.00 Pain Relevance 0.08
Chem. 1995) [35] make a schematic diagram of active site showing key binding features of thrombin.
thrombin Binding (binding) of
12) Confidence 0.26 Published 2008 Journal The Open Biochemistry Journal Section Body Doc Link PMC2627521 Disease Relevance 0 Pain Relevance 0
The surprisingly low value of Ki of the compound 3 modified with the lauric acid residue motivated us to conduct additional researches to get an understanding of the interaction of such compound at the binding site of thrombin.
thrombin Binding (binding) of
13) Confidence 0.26 Published 2008 Journal The Open Biochemistry Journal Section Body Doc Link PMC2627521 Disease Relevance 0.06 Pain Relevance 0
Involving into this sequence aromatic or aliphatic (in general hydrophobic) moieties increases the affinity to enzyme by supplementary interactions with the hydrophobic region of thrombin, immediately adjacent to the active site.
thrombin Binding (interactions) of
14) Confidence 0.26 Published 2008 Journal The Open Biochemistry Journal Section Body Doc Link PMC2627521 Disease Relevance 0.08 Pain Relevance 0
In present medical practice the natural thrombin inhibitor – heparin and its low-molecular fragments are widely used, which act by formation of the triple complex with thrombin and antithrombin III– as anticoagulants of direct action (Mousa SA.
thrombin Binding (complex) of
15) Confidence 0.26 Published 2008 Journal The Open Biochemistry Journal Section Body Doc Link PMC2627521 Disease Relevance 0.23 Pain Relevance 0.14
X-ray structural analysis data of complexes of thrombin with inhibitors enabled to design new inhibitors of the enzyme with high efficiency (Bode A Protein Science 1992) [11].
thrombin Binding (complexes) of
16) Confidence 0.26 Published 2008 Journal The Open Biochemistry Journal Section Body Doc Link PMC2627521 Disease Relevance 0.32 Pain Relevance 0.11
To study the effects of protein C and factor VII on procoagulant activity, prothrombin time was measured after the addition of activated protein C and factor VII to protein C-deficient plasma.
prothrombin Binding (time) of in plasma
17) Confidence 0.24 Published 1992 Journal Thromb. Res. Section Abstract Doc Link 1440517 Disease Relevance 0.87 Pain Relevance 0.07
Some studies do not find an association between the prothrombin mutation and RM [123-125], while other studies do [111,112].
prothrombin mutation Neg (not) Binding (association) of associated with habitual abortion
18) Confidence 0.24 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC305329 Disease Relevance 0.62 Pain Relevance 0
It is not clear as yet, whether severe preeclampsia is associated with the prothrombin and MTHFR mutations.


prothrombin Spec (whether) Binding (associated) of associated with pre-eclampsia
19) Confidence 0.24 Published 2003 Journal Reprod Biol Endocrinol Section Body Doc Link PMC305329 Disease Relevance 1.80 Pain Relevance 0
Its 20-amino acid molecule combines a carboxy-terminal region that recognizes thrombin's fibrin (ogen)-binding site, and an amino-terminal tetrapeptide that inhibits the active site of thrombin [56].
thrombin Binding (recognizes) of
20) Confidence 0.23 Published 2010 Journal J Cardiothorac Surg Section Body Doc Link PMC2987921 Disease Relevance 0.37 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox